A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
about
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseDecreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectorisSystematic adjudication of myocardial infarction end-points in an international clinical trialDisagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyAntiplatelet therapy from clinical trials to clinical practice.Clinical use of new antithrombotic therapies for medical management of acute coronary syndromesOrbofiban: an orally active GPIIb/IIIa platelet receptor antagonistPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionCommon variations in platelet glycoproteins: pharmacogenomic implicationsUnstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapyClinical trials of glycoprotein IIb/IIIa inhibitorsAntiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trialDifferential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practiceElderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapiesCurrent strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesNon-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitionerPlatelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyThe risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.Dual pathway therapy in acute coronary syndrome.Recent advances in ischaemic heart disease.Acute profound thrombocytopenia following abciximab therapy.Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.Drug-induced and drug-dependent immune thrombocytopenias.Emerging anticoagulant and thrombolytic drugs.Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary interventionTirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.Thrombocytopenia following percutaneous coronary intervention.Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.Safety evaluation of tirofiban.Severe thrombocytopenia following tirofiban infusionRoutine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis.Tirofiban-Induced Thrombocytopenia Occurring with Crohn's Disease
P2860
Q24202522-4AF315CA-CCCD-4309-AB68-0344FDBAE41FQ24202999-16E1435E-D2D3-417C-8AA1-850F041316A5Q24235385-F4F6E81A-B990-4D68-BCC0-A9E81BA09C87Q24793321-83F67B2A-6ED5-4AB4-B423-8BF45EEEDA40Q24797376-2906B2C3-78E6-498E-9AF5-12EEA5C9F09BQ24805625-F7572012-5031-4AAB-AB81-804EAB1CE9EBQ24805692-DF806582-D051-424E-A0D3-108DDC057528Q28176354-4A7454A2-44CC-4FCC-AC39-D40C63F79913Q28177271-9BDEDE7B-7034-4963-BF9E-7A615C5EFE55Q28181764-E600AFA6-1C30-44D5-B67B-4482D507802FQ28191096-3189E21D-9BA7-4CEA-8CE2-E53D3D94AA69Q28191774-5AE41CB4-CFA0-4D82-A6DC-2BFCB946E909Q28192025-7E51CBBC-D8B9-42FF-9060-0F930E7EF6F8Q28193162-4CBFF5D9-5488-4261-B892-9A42EDE8D073Q28193219-C8181543-CC4E-4618-898F-C8921A2450FDQ28194967-6B908336-6890-4196-B049-94F5CC0D029EQ28195598-9354F6E5-6E10-4651-ABEB-A14E98DE0ED5Q28196885-E9BE8003-A8F5-4BD1-9543-C3FE33A4B7CDQ28199725-0FE205AE-1403-485A-84F9-7D19A1716960Q28211708-B2BAB754-AC48-4B16-8E56-A3C532B6E8F8Q28219354-8965AC21-65D5-461F-A6E2-B026C924B52EQ28239975-058E331E-30A0-4623-9341-847823221AA2Q30234909-F0134C19-448E-472A-936A-21FB02817DB8Q30252011-BA425062-1CC7-4847-BE1C-93E2FABAD93AQ30912640-B8DF5BDD-2C48-4034-BC52-B357EE78FACAQ33333419-883C7566-CA7F-4973-B536-6800BADBE4B8Q33336702-DC1209EE-FC69-4000-B062-48971DBDD77BQ33339739-83251898-6DEA-49A7-AA22-49523F5EE978Q33367019-04A78319-F1F1-4A50-932A-F3B3576B0E5EQ33367950-9ECEA4E1-1E2B-402C-985F-09C5938FE4BEQ33369310-70E10F7B-ECBF-47A0-9186-0D8580158DA7Q33380104-6ABD1699-F91B-4F0C-86C6-9C223C1FC40CQ33386229-9896DF7E-E703-46D6-85EB-F8703F3EC326Q33387648-3BAECA38-9D55-4C3D-AEEF-94FB646142BFQ33388452-A470ED16-42F7-4045-8CD3-D5C20535143DQ33391065-FD207C59-68F7-4296-8214-270402F577D5Q33398606-6C530D0A-8051-4A3B-B647-25163CA7F26AQ33406801-37D63F48-CF7D-4BA5-8445-3F9CBDB13B09Q33414284-04B211F9-A554-470D-8D5F-E7AB83E390A8Q33431961-F896DD39-6340-4203-9F98-80F5C3EF9E6E
P2860
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@ast
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@en
type
label
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@ast
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@en
prefLabel
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@ast
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@en
P1476
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
@en
P2093
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
P304
P356
10.1056/NEJM199805213382103
P407
P577
1998-05-01T00:00:00Z